Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Wednesday

Oruka Therapeutics (NASDAQ:ORKA) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Oruka Therapeutics to post earnings of ($0.52) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, analysts expect Oruka Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Stock Up 3.7%

Shares of Oruka Therapeutics stock opened at $68.95 on Wednesday. The firm has a market cap of $3.46 billion, a P/E ratio of -37.07 and a beta of -0.20. Oruka Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $91.00. The business has a 50-day moving average price of $50.30 and a 200 day moving average price of $37.30.

Analyst Ratings Changes

Several brokerages recently weighed in on ORKA. Barclays boosted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, April 30th. Stifel Nicolaus boosted their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. HC Wainwright boosted their price objective on Oruka Therapeutics from $75.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Insider Activity at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider directly owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This trade represents a 18.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 23,765 shares of company stock valued at $1,089,745 over the last ninety days. Corporate insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in ORKA. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $51,280,000. Paradigm Biocapital Advisors LP bought a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $51,840,000. Remedium Capital Partners LLC bought a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $47,054,000. Deep Track Capital LP grew its holdings in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Oruka Therapeutics by 112.2% during the fourth quarter. State Street Corp now owns 1,383,847 shares of the company’s stock valued at $41,944,000 after purchasing an additional 731,819 shares during the last quarter. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.